Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007
UDIZ-007 demonstrated robust anti-tumor activity, favorable PK and safety profiles, as well as selective binding to PD-1-expressing tissues, supporting its clinical development as a potential cancer immunotherapy.